rs193922146

Variant summary

Our verdict is Benign. Variant got -16 ACMG points: 0P and 16B. BP4_StrongBP6_Very_StrongBS2

The ENST00000225964.10(COL1A1):​c.2236-17C>G variant causes a splice polypyrimidine tract, intron change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.000929 in 1,610,566 control chromosomes in the GnomAD database, including 6 homozygotes. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Likely benign (★★).

Frequency

Genomes: 𝑓 0.0013 ( 0 hom., cov: 31)
Exomes 𝑓: 0.00089 ( 6 hom. )

Consequence

COL1A1
ENST00000225964.10 splice_polypyrimidine_tract, intron

Scores

2

Clinical Significance

Benign/Likely benign criteria provided, multiple submitters, no conflicts B:5

Conservation

PhyloP100: -0.812
Variant links:
Genes affected
COL1A1 (HGNC:2197): (collagen type I alpha 1 chain) This gene encodes the pro-alpha1 chains of type I collagen whose triple helix comprises two alpha1 chains and one alpha2 chain. Type I is a fibril-forming collagen found in most connective tissues and is abundant in bone, cornea, dermis and tendon. Mutations in this gene are associated with osteogenesis imperfecta types I-IV, Ehlers-Danlos syndrome type VIIA, Ehlers-Danlos syndrome Classical type, Caffey Disease and idiopathic osteoporosis. Reciprocal translocations between chromosomes 17 and 22, where this gene and the gene for platelet-derived growth factor beta are located, are associated with a particular type of skin tumor called dermatofibrosarcoma protuberans, resulting from unregulated expression of the growth factor. Two transcripts, resulting from the use of alternate polyadenylation signals, have been identified for this gene. [provided by R. Dalgleish, Feb 2008]

Genome browser will be placed here

ACMG classification

Classification made for transcript

Verdict is Benign. Variant got -16 ACMG points.

BP4
Computational evidence support a benign effect (BayesDel_noAF=-0.66).
BP6
Variant 17-50190941-G-C is Benign according to our data. Variant chr17-50190941-G-C is described in ClinVar as [Likely_benign]. Clinvar id is 35909.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars. Variant chr17-50190941-G-C is described in Lovd as [Likely_benign].
BS2
High AC in GnomAd4 at 196 AD gene.

Transcripts

RefSeq

Gene Transcript HGVSc HGVSp Effect #exon/exons MANE Protein UniProt
COL1A1NM_000088.4 linkuse as main transcriptc.2236-17C>G splice_polypyrimidine_tract_variant, intron_variant ENST00000225964.10 NP_000079.2
COL1A1XM_005257058.5 linkuse as main transcriptc.2236-17C>G splice_polypyrimidine_tract_variant, intron_variant XP_005257115.2
COL1A1XM_005257059.5 linkuse as main transcriptc.1318-17C>G splice_polypyrimidine_tract_variant, intron_variant XP_005257116.2
COL1A1XM_011524341.2 linkuse as main transcriptc.2038-17C>G splice_polypyrimidine_tract_variant, intron_variant XP_011522643.1

Ensembl

Gene Transcript HGVSc HGVSp Effect #exon/exons TSL MANE Protein Appris UniProt
COL1A1ENST00000225964.10 linkuse as main transcriptc.2236-17C>G splice_polypyrimidine_tract_variant, intron_variant 1 NM_000088.4 ENSP00000225964 P1
COL1A1ENST00000476387.1 linkuse as main transcriptn.585-17C>G splice_polypyrimidine_tract_variant, intron_variant, non_coding_transcript_variant 2
COL1A1ENST00000494334.1 linkuse as main transcript upstream_gene_variant 2

Frequencies

GnomAD3 genomes
AF:
0.00129
AC:
196
AN:
152086
Hom.:
0
Cov.:
31
show subpopulations
Gnomad AFR
AF:
0.0000483
Gnomad AMI
AF:
0.00
Gnomad AMR
AF:
0.000196
Gnomad ASJ
AF:
0.000576
Gnomad EAS
AF:
0.00
Gnomad SAS
AF:
0.00
Gnomad FIN
AF:
0.00754
Gnomad MID
AF:
0.00
Gnomad NFE
AF:
0.00157
Gnomad OTH
AF:
0.000958
GnomAD3 exomes
AF:
0.00105
AC:
264
AN:
250740
Hom.:
0
AF XY:
0.000944
AC XY:
128
AN XY:
135598
show subpopulations
Gnomad AFR exome
AF:
0.00
Gnomad AMR exome
AF:
0.0000869
Gnomad ASJ exome
AF:
0.000696
Gnomad EAS exome
AF:
0.00
Gnomad SAS exome
AF:
0.0000327
Gnomad FIN exome
AF:
0.00466
Gnomad NFE exome
AF:
0.00129
Gnomad OTH exome
AF:
0.00114
GnomAD4 exome
AF:
0.000892
AC:
1301
AN:
1458480
Hom.:
6
Cov.:
33
AF XY:
0.000966
AC XY:
701
AN XY:
725740
show subpopulations
Gnomad4 AFR exome
AF:
0.0000299
Gnomad4 AMR exome
AF:
0.0000447
Gnomad4 ASJ exome
AF:
0.00115
Gnomad4 EAS exome
AF:
0.00
Gnomad4 SAS exome
AF:
0.0000232
Gnomad4 FIN exome
AF:
0.00437
Gnomad4 NFE exome
AF:
0.000892
Gnomad4 OTH exome
AF:
0.000713
GnomAD4 genome
AF:
0.00129
AC:
196
AN:
152086
Hom.:
0
Cov.:
31
AF XY:
0.00159
AC XY:
118
AN XY:
74310
show subpopulations
Gnomad4 AFR
AF:
0.0000483
Gnomad4 AMR
AF:
0.000196
Gnomad4 ASJ
AF:
0.000576
Gnomad4 EAS
AF:
0.00
Gnomad4 SAS
AF:
0.00
Gnomad4 FIN
AF:
0.00754
Gnomad4 NFE
AF:
0.00157
Gnomad4 OTH
AF:
0.000958
Alfa
AF:
0.00230
Hom.:
0
Bravo
AF:
0.000710

ClinVar

Significance: Benign/Likely benign
Submissions summary: Benign:5
Revision: criteria provided, multiple submitters, no conflicts
LINK: link

Submissions by phenotype

not provided Benign:3
Benign, criteria provided, single submitterclinical testingAthena DiagnosticsDec 12, 2017- -
Likely benign, criteria provided, single submitterclinical testingCeGaT Center for Human Genetics TuebingenJul 01, 2023COL1A1: BS1 -
Likely benign, criteria provided, single submitterclinical testingGeneDxApr 24, 2018- -
not specified Benign:1
Benign, criteria provided, single submitterclinical testingWomen's Health and Genetics/Laboratory Corporation of America, LabCorpMay 03, 2023Variant summary: COL1A1 c.2236-17C>G alters a non-conserved nucleotide located close to a canonical splice site and therefore could affect mRNA splicing, leading to a significantly altered protein sequence. 4/4 computational tools predict no significant impact on normal splicing. However, these predictions have yet to be confirmed by functional studies. The variant allele was found at a frequency of 0.0011 in 250740 control chromosomes (gnomAD). The observed variant frequency is approximately 37 fold of the estimated maximal expected allele frequency for a pathogenic variant in COL1A1 causing Osteogenesis Imperfecta phenotype (2.8e-05), strongly suggesting that the variant is benign. To our knowledge, no occurrence of c.2236-17C>G in individuals affected with Osteogenesis Imperfecta and no experimental evidence demonstrating its impact on protein function have been reported. Four clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014 and all laboratories classified the variant as benign/likely benign. Based on the evidence outlined above, the variant was classified as benign. -
Osteogenesis imperfecta type I Benign:1
Benign, criteria provided, single submitterclinical testingLabcorp Genetics (formerly Invitae), LabcorpJan 21, 2024- -

Computational scores

Source: dbNSFP v4.3

Name
Calibrated prediction
Score
Prediction
BayesDel_noAF
Benign
-0.66
CADD
Benign
2.0
DANN
Benign
0.77

Splicing

Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
0.040
Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

LitVar

Below is the list of publications found by LitVar. It may be empty.

Other links and lift over

dbSNP: rs193922146; hg19: chr17-48268302; API